MELBOURNE, Australia & NEW YORK--(BUSINESS WIRE)--Anadis Limited (ASX: ANX), a research driven biopharmaceutical company focused on polyclonal antibodies to address human disease, announced today important progress concerning its accelerated program to develop a nasal antibody spray to provide immediate post-exposure prophylaxis against a range of influenza viruses.
